NCT06709235View on ClinicalTrials.gov

Assessing Refractoriness and Infectious Survival Events in AML

CompletedOBSERVATIONAL

Enrollment

280

Participants

Timeline

Start Date

May 1, 2024

Primary Completion Date

May 1, 2024

Study Completion Date

July 30, 2024

Conditions

Acute Myeloid Leukemia (AML)

Trial Locations (1)

Unknown

Hopital Lyon Sud, Pierre-Bénite

All Listed Sponsors

lead

Hospices Civils de Lyon

OTHER

NCT06709235 - Assessing Refractoriness and Infectious Survival Events in AML | Biotech Hunter | Biotech Hunter